Wall Street analysts forecast that Arsanis Inc (NASDAQ:ASNS) will report ($0.49) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Arsanis’ earnings. The business is scheduled to announce its next quarterly earnings results on Monday, November 12th.
According to Zacks, analysts expect that Arsanis will report full-year earnings of ($3.12) per share for the current financial year, with EPS estimates ranging from ($3.46) to ($2.46). For the next fiscal year, analysts anticipate that the firm will post earnings of ($2.54) per share, with EPS estimates ranging from ($3.56) to ($1.51). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Arsanis.
Arsanis (NASDAQ:ASNS) last announced its quarterly earnings data on Monday, August 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.03).
Shares of ASNS traded down $0.04 on Thursday, hitting $1.77. 44,452 shares of the stock traded hands, compared to its average volume of 176,690. The company has a debt-to-equity ratio of 0.20, a current ratio of 5.54 and a quick ratio of 5.54. Arsanis has a 1 year low of $1.70 and a 1 year high of $28.69.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in Arsanis during the first quarter worth approximately $4,029,000. Granahan Investment Management Inc. MA purchased a new position in Arsanis during the second quarter worth approximately $365,000. Northern Trust Corp purchased a new position in Arsanis during the first quarter worth approximately $735,000. Millennium Management LLC purchased a new position in Arsanis during the fourth quarter worth approximately $299,000. Finally, JPMorgan Chase & Co. raised its stake in Arsanis by 6.4% during the first quarter. JPMorgan Chase & Co. now owns 247,415 shares of the company’s stock worth $5,663,000 after purchasing an additional 14,819 shares during the period. 68.70% of the stock is currently owned by institutional investors and hedge funds.
Arsanis Company Profile
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.
Recommended Story: Dow Jones Industrial Average (DJIA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.